Orchestra BioMed Holdings, Inc.OBIONASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+38.4%
5Y CAGR+34.0%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+38.4%/yr
Annual compound
5Y CAGR
+34.0%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
4.3x
Strong expansion
Streak
4 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$58.19M+35.9%
2024$42.80M+26.6%
2023$33.82M+54.1%
2022$21.95M+70.2%
2021$12.89M-4.4%
2020$13.48M-